EGFR and non-small cell lung carcinoma: Although second-generation EGFR inhibitors such as neratinib, afatinib, and dacomitinib exhibited promising anti-T790M activity in the laboratory, their clinical activity in T790M+ NSCLC was poor, with RR less than 10% among patients resistant to gefitinib or erlotinib (28–30).